US Dollar vs Yen

登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。

登録

ARGX

Argen X (ARGX)

Argen X SE

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:EU:ARGX

1 2 3 4 5 6 7 8 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/09	14 : 00	GlobeNewswire Inc.	argenx Reports First Quarter 2024 Financial Results and Provides Business Update	EU:ARGX	Argen X SE
2024/05/08	06 : 30	GlobeNewswire Inc.	argenx announces results of Annual General Meeting of Shareholders	EU:ARGX	Argen X SE
2024/05/07	14 : 00	GlobeNewswire Inc.	argenx to Present at BofA Securities 2024 Health Care Conference	EU:ARGX	Argen X SE
2024/05/02	14 : 00	GlobeNewswire Inc.	argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024	EU:ARGX	Argen X SE
2024/04/16	14 : 00	GlobeNewswire Inc.	argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease	EU:ARGX	Argen X SE
2024/03/27	15 : 00	GlobeNewswire Inc.	argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease	EU:ARGX	Argen X SE
2024/03/27	05 : 00	GlobeNewswire Inc.	argenx Announces Annual General Meeting of Shareholders on May 7, 2024	EU:ARGX	Argen X SE
2024/03/26	15 : 00	GlobeNewswire Inc.	argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia	EU:ARGX	Argen X SE
2024/03/08	06 : 01	GlobeNewswire Inc.	argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting	EU:ARGX	Argen X SE
2024/02/29	15 : 00	GlobeNewswire Inc.	argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update	EU:ARGX	Argen X SE
2024/02/26	15 : 00	GlobeNewswire Inc.	argenx to Present at Upcoming Investor Conferences	EU:ARGX	Argen X SE
2024/02/22	15 : 00	GlobeNewswire Inc.	argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024	EU:ARGX	Argen X SE
2024/02/20	15 : 00	GlobeNewswire Inc.	argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy	EU:ARGX	Argen X SE
2024/01/18	15 : 00	GlobeNewswire Inc.	argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis	EU:ARGX	Argen X SE
2024/01/08	15 : 00	GlobeNewswire Inc.	argenx Highlights 2024 Strategic Priorities	EU:ARGX	Argen X SE
2024/01/02	15 : 00	GlobeNewswire Inc.	argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference	EU:ARGX	Argen X SE
2023/12/20	15 : 00	GlobeNewswire Inc.	argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus	EU:ARGX	Argen X SE
2023/11/28	15 : 00	GlobeNewswire Inc.	argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia	EU:ARGX	Argen X SE
2023/11/16	21 : 40	GlobeNewswire Inc.	argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia Gravis	EU:ARGX	Argen X SE
2023/11/01	15 : 00	GlobeNewswire Inc.	argenx to Present at Upcoming Investor Conferences	EU:ARGX	Argen X SE
2023/11/01	15 : 00	GlobeNewswire Inc.	argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions	EU:ARGX	Argen X SE
2023/10/31	15 : 00	GlobeNewswire Inc.	argenx Reports Third Quarter 2023 Financial Results and Provides Business Update	EU:ARGX	Argen X SE
2023/10/24	14 : 00	GlobeNewswire Inc.	argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023	EU:ARGX	Argen X SE
2023/09/21	14 : 00	GlobeNewswire Inc.	argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis	EU:ARGX	Argen X SE
2023/09/15	14 : 00	GlobeNewswire Inc.	argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Gravis	EU:ARGX	Argen X SE
2023/08/30	14 : 00	GlobeNewswire Inc.	argenx to Present at Upcoming Investor Conferences	EU:ARGX	Argen X SE
2023/07/27	14 : 00	GlobeNewswire Inc.	argenx Reports Half Year 2023 Financial Results and Provides Second Quarter Business Update	EU:ARGX	Argen X SE
2023/07/25	05 : 30	GlobeNewswire Inc.	argenx announces closing of global offering	EU:ARGX	Argen X SE
2023/07/20	14 : 00	GlobeNewswire Inc.	argenx to Report Half Year 2023 Financial Results and Second Quarter Business Update on July 27, 2023	EU:ARGX	Argen X SE
2023/07/20	06 : 58	GlobeNewswire Inc.	argenx announces full exercise of underwriters’ option to purchase additional ADSs	EU:ARGX	Argen X SE

Showing the most relevant articles for your search:EU:ARGX

1 2 3 4 5 6 7 8 次へ >>

Fresh Tracks Therapeutics

Luzerner Kantonalbank

Churchill Capital Corp VI

Shuttle Pharmaceuticals

Musk Token (MuskSwap)

Ambipar Participacoes e ... ON

Teva- Pharmaceutical Ind...

Palantir Technologies

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約